BioSpace News Archive

Latest data from the CIRLL study to be presented at ASCO 2021 remain encouraging, demonstrate good, continued enrollment, are consistent with previous results and are updated over data contained in abstract #7556 released today

Thermo Fisher Scientific Inc., the world leader in serving science, announced that its Board of Directors has authorized a quarterly cash dividend of $0.26 per common share, payable on July 15, 2021, to shareholders of record as of June 15, 2021.

Durable Responses Observed in Second Cohort of Patients in Pivotal EV-201 Trial of PADCEV and in Initial First-Line Cohort of the EV-103 Trial Evaluating PADCEV in Combination with KEYTRUDA® (pembrolizumab)

LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer New Data From the Phase 2 FIGHT Trial with Bemarituzumab in Advanced Gastric and Gastroesophageal Junction Cancers

- Maturing data from the Phase 1 dose-escalation cohort for STRO-002 showed a median progression-free survival of 7.2 months - One patient achieved a CR and nine patients achieved a PR, of which four were confirmed PRs. Median duration of response on the five confirmed responders was 5.8 months - Data on STRO-002 from the dose-escalation cohort to be presented as a poster at ASCO and available as part of the Company Corporate Presentation has a cut-off date of April 23, 2021

New momelotinib analysis examining the association between transfusion independence and overall survival to be presented

OnQuality Pharmaceuticals today announced that abstracts for the NOVA-II clinical trial evaluating OnQuality’s lead candidate, OQL011, have been selected for presentations at two upcoming meetings: a Trial in Progress poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting,

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that sixteen abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4, 2021

Scheduled to present results and trial designs on five therapeutic candidates from 13 clinical trials across eight types of cancer Featuring three anti-PD-1 combinations and the continuing evaluation of next-generation BTK inhibitor zanubrutinib

Data to highlight promising early efficacy of patritumab deruxtecan in patients with TKI-resistant, EGFR-mutated locally advanced or metastatic non-small cell lung cancer